


Fig.1. Location of topographical epitopes on CD30 molecule

Fig 2a. Amino acid sequences of the variable regions of anti-CD30 MAbs


11g 79	7	rig za. Ammino acta sequentees of are target	0				
		000	CDR1	FR2	CDR2	PR3	CDR3 FR4
		144			9	6 8 4	10 11
H	SEQ 10	1 2 1	1 12345AB	12345AB 67890123456789	12ABC3456789012345	67890123456789012ABC345678901234	567890ABCDEFGHIJK12 34567890123
	ğ	123456 / 070125456 / 07025756 / 0	111070	S.IWa.Indodecomm	MIWGVENTDYNSALKS	RLSISKDNSKSQVFLKMNSLQSDDTAMYYCAR	MDLGLYGMNY WGQGISVTVSA
16	7	QVQLKESGPGLVTPSQSLSITCTVSGFSLS	VISTU			want.rankssstaymolissi.tsedsavyfcar	RETGRGAWFTY WGQGTLVTVSA
T.	m	QVQLQQSGAELVRPGSSVKISCKASGYTFS	SYMMIN	WMKQRPGQGLEWIG		CALL THE PROCESS TO AND THE PROPERTY OF THE PR	RGSYDGNPFAY WGQGTLVSVSA
T13	4	QVQLQQSGAELAKPGASVKMSCKASGYTFT	TYWMH	WVKQRPGQGLEWIG	YINPSIGYIDYNEKFKU	WILLIAM SOUTH THE STATE OF THE	
T14	ហ	EVQLVESGGGLVKPGGSLKLSCGVSGFTFS	DYYMY	WVRQTPEKRLEWVA	SISSGGSYTYYSDSVKG	KLI LSKUNI KNNLI LQUISSINGESTATA	1
T24	v	OVOLOOPGAELVRPGASVKLSCKASGYSFT	SYWID	WVKQRPGQGLEWIG	NIYPSNAYTNYNOKFKD	KATLITVDKSSSTAYMQLSSPISEDSAVIICIS	
: u		OMI. KESGPGII. OPSOTUSLITCSFSGFSLN	TSGVGVG	TSGVGVG WIRQPSGKGLEWLA	HIWWDDDERYNPVLKS	RLTISKOTSSNOVFLKIANVDTADSATYYCVR	SMVAWF
671		STUTES TO	DYYM	WVROPPGKALEWLG	FIRNKANGYTTEFSASVMG	RFTISRDDSQSILYLQMNTLRAEDSATYYCAR	DPPYGNPHYYAMDY WGQGTSVTVSS
H6F1-1	20	EVELVES GGG LYZEGGS LICENSTRUCTURE CONTRACTOR CONTRACTO	1000	り18年1500日日の77年	NTNPSNGGTNYNEKFKS	KATLITIDKSSSTAYMQLSSLTSEDSAVYYCAR RTETAQASPF	RTETAQASPFAY WGQGTLVTVSS
CI75	0	EVQLKQSGTELVKPGASVKLSCKASGTIFT	ULIM I C		Cathologicalista	WATE TO BE STATED SAVYY CAK	KTTOTTWGFPF WGQGTLVTVSS
K4-4	10	QVKLQESGTELAKPGAAVKMSCKASGYTFT	DYWMH	WVKQRPGQGLEWIG	YINPNTAYIDINQKEKD	WI DIAD ASSESSMENT OF THE PROPERTY OF THE PROP	Va
T420	11	OVOLOOSGAELAKPGASVKMSCKASGYTFT	SYWMH	WVKQRPGQDLEWIG	YINPSTDYTDYNQKFKD	KATLTADKSSSTAYMQLSSLTSEDSAVIYCAI	
	:		SYWMN	WVKQRPGQGLEWIG	MIHP-SDSETRLNOKFKD	RATLITVDKSSSTAYMQLSSPTSEDSAVYYCAS	1
775	1 :		NYWIN	WVKQRPGQGLEWIG	NIYP-SDSRSNYNQKFKD	KATLTVDKPSSTAYMQLSSPTSEDSAVYYCTL	;
T405	7		AUWUSAL	TEGMOVS WIROPSGKOLEWLA	HIYWDDDKRYNPSLKS	<b>RLTISKDISSNQVFLKITSVDTADTATYYCAR</b>	RADGLYFYLDV WGAGTTVTVSS
1105	7			O LINE LUADOUOUM	SAJBSNYGTNEGEWIM	RLSISKDNSKSOVFLKVNSLQTDDTARYYCAR	PSTGTLFAY WGQGTLVTVSA
T201	38	QVQLKESGPGLVAPSQSLSITCTVSGFSLI	DYGVS	WVKQFFGNGLERLM			GSY WGOGTLVTVSA
T408	40	QVQLQQPGAELVRPGASVKLSCKASGYTFT	SYWIN	WVKQRPGQGLEWIG	NIYPSDSYSNYNQKFKU		<b>.</b>


MAbs
i-CD30
of ant
regions
variable
E the
acid sequences of
acid
Amino
Fig 2b.

		FR1	CDR1	FR2	CDR2	E 25	CDR3	FR4
VL	VL ID	           	 3 4567ABCDEF8901234	567890123456789	   5   0123456		9   9012345ABCDEF67	   1   890123456A789
T6	15	DIVMTQSQKFMSTSVGDRVSVTC KASQNVGTNVA	KASQNVGTNVA	WYQQKPGQSPKALFY	SASYRYS	GVPDRFIGSGSGTVFTLTISNVQSEDLAEYFC	QQYNTYPLT	FGSGTKLEIERA
17	16	DIVLTQSPASLAVSLGQRATISC	RASESLEY-YGTTLMQ	WYQQKPGQPPKLLIY	AASNVES	GVPARFSGSGSGTDFSLNIHPVEEDDIAMYFC	HQSRKVPST	FGGGTKLEIKRAD
T13	11	DIVMTQSHKFMSTSVGDRVTITC	KASQDVSTAVA	WYQQKPGHSPKLLIY	WASTRHT	GVPDRFTGSGSGTDYTLTISSVQVEDLALYYC	QQHYSTPFT	FGSGTKLEIKRA
T14-A	18	DVVMTQTPLSLPVSLGDQASISC	RSSQNLIHS-NGNAYLQ	WYLQKPGQSPKLLIY	KVSNRFS	GVPDRFSGSGSGTDFALKIIRVEAEDLGVYFC	SQTTHVPYT	FGGGTKLEIKRAD
T14-B	19	DIVLTQSPASLAVSLGQRATISC	RASESLEY-YGTTLMQ	WYQQKPGQPPKLLIY	AASNVES	GVPARFSGSGSTDFSLNIHPVEEDDIAMYFC	HOSRKVPST	FGGGTKLEIKRAD
T21	20	DIQMNQSPSSLSASLGDTITITC	HASQNINVWLT	WYQQKPGNIPQLLIY	KASNLHT	GVPSRFSGSGSGTGFTLTISSLQPEDIATYYC	QQGQSYPLT	FGAGTKLELKRA
T24	21	DIQMTQTTSSLSASLGDRVTISC	RASQDISNYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISNLEQEDIATYFC	QQVNTLPRT	FGGGTKLEIKRA
125	22	DIVMSQSPSSLAVSVGEKFTVNC	KSSQSLLYSSNOKNFLA	WYQQKPGQSPKLLIY	WASTRES	GVPDRFIGSGSGTDFTLTISSVKAEDLAVYYC	QQHYRYPWT	FGGGTKLEIKRAR
HeFi-I 23	I 23	DIVLTQSPASLAVSLGQRATISC	RASKSVSASGYNYMH	<b>М</b> ХQQКАGQРРКLLІН	LASNLES	GVPARFSGSGGGTDFTLNIHPVEEEDASTYYC	QHSGELPFT	FGSGTKLEIKRA
CL2	24	DIVMTQSHKFMSTSVGDRVSVTC	KASQNVGTNVA	WYQQKPGQSPKALIY	SASTRYS	GVPDRFTGSGSGTDFTLTISNVQSEDLAEYFC	QQYNSYPFT	FGSGTKLEIK
K1-4	25	DIVLTQSHKSMAMSVGERVTLSC	KASENVDSFVS	WYQQKPGQSPKALIY	GASNRHS	GVPDRFAGSGSGRDFTLTISSVQAEDLADYHC	QQNYRYPLT	FGAGTKLEIK
T420	56	DIVMTQSHKFMSTSVGDRVSITC	KASQDVSTAVA	WYQQKPGQSPKLLIY	WASTRHT	GVPDRFTGSGSGTDYSLTISSVQAEDLAVYYC	QQHYRTPFT	FGSGTKLEIKR
T427	27	DIVLTQSPTSLAVSLGQRATISC	RASESVDS-YGNSFMH	WEQQKPGQPPKLLIY	RASNLES	GIPARFSGSGSWTDFTLTINPVEADDVATYYC	QQSNEDPRT	FGGGTKLEIKR
T405	28	DVVMTQTPLTLSVTIGQPASISC	KSSQSLSDS-DGKTYLN	WLLQRPGQSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGAHFPRT	FGGGTKLEIKR
1105	53	DIVMTQSQKFMSTSVGDRVSVTC	KASQNVNTNVA	WYQQKPGQSPEALIY	SASYRYS	GVPDRFTGSGSGTDFTLTISNVQSEDLAEYFC	QQYNSYPLT	FGSGTKLEIKR
T201	39	EIVLTQSPTTMAASPGERITFTC	SASSGISSIYLH	WYQQKPGFSPKLLIY	RTSNLAS	GVPPRFSGSGSGTSYSLTIGIMEAEDVATYYC	QQGSSIPLT	FGAGTKLELKRA
T408	41	DVVMTQTPLTLSVTIGQPASISC	KSSQSLSDS-DGKTYLN	WLLQRPGQSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGAHFPRT	FGGTKLEIKRA




BEST AVAILABLE COPY






CDC of anti-CD30 antibody in the absence of secondary antibody (15-h postincubation)


Fig. 6A Karpas299 (CD30 positive)



7/9



BEST AVAILABLE COPY



BEST AVAILABLE COPY